Johnson & Johnson (JNJ) reported $99.33B of revenue for the twelve months ended Sep 27, 2026. That is up 7.8% from the year before. Revenue for fiscal 2025 was $94.19B.

Yes. Johnson & Johnson earned $16.09B in net income for the twelve months ended Sep 27, 2026, a net margin of 16.2%.

How much cash and debt does JNJ have?

Johnson & Johnson reported $16.91B in cash and cash equivalents and $44.65B of debt on its most recent balance sheet in SEC filings.

How fast is JNJ revenue growing?

Johnson & Johnson's revenue changed +6.0% in fiscal 2025, to $94.19B. Its compound annual growth rate was +2.7% over 5 years.

What is JNJ gross margin?

Johnson & Johnson's gross profit was $67.11B on $99.33B of revenue for the twelve months ended Sep 27, 2026, a gross margin of 67.6%.

What is JNJ free cash flow?

Johnson & Johnson generated $20.59B of free cash flow for the twelve months ended Sep 27, 2026, which is operating cash flow of $26.16B less capital expenditures.

What is JNJ earnings per share?

Diluted earnings per share were $6.58 for the twelve months ended Sep 27, 2026, from SEC filings, restated for any stock split those filings show.

When did JNJ last report financial results?

The latest statements here come from Johnson & Johnson's 10-Q filed on Oct 21, 2026, covering the period ended Sep 27, 2026.

Where does this JNJ financial data come from?

Quantisnow builds these statements from the structured XBRL data Johnson & Johnson files with the SEC. It is provided for information only and is not investment advice.

Financials · JNJ

Johnson & Johnson (JNJ) financials

For the twelve months ended Sep 27, 2026, Johnson & Johnson reported $99.33B of revenue and $16.09B of net income.

Revenue, TTM: $99.33B
Revenue growth, YoY: +7.8%
Net income, TTM: $16.09B
Net income growth, YoY: -35.9%
Net margin: 16.2%
Free cash flow, TTM: $20.59B
EPS, diluted, TTM: $6.58
EPS growth, YoY: -36.5%
Cash: $16.91B
Total debt: $44.65B
P/E: 41.31
P/S: 6.69
Market cap: $664.95B

Annual revenue$94.19B

FY2016FY2025

Annual net income$26.80B

FY2016FY2025

Annual free cash flow$19.70B

FY2016FY2025

JNJ revenue and earnings growth

JNJ revenueQ3 2026$25.40B

Quarter YoY: +5.9%
QoQ: +0.4%
FY YoY: +6.0%
5Y CAGR: +2.7%

JNJ revenue was $25.40B in fiscal Q3 2026 (ended Sep 27, 2026), up 5.9% from a year earlier and up 0.4% from the prior quarter. For the full fiscal 2025 it was $94.19B, up 6.0% from fiscal 2024. Compound annual growth was +2.7% over 5 years. It rose in 8 of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

JNJ net incomeQ3 2026$210.00M

Quarter YoY: -95.9%
QoQ: -96.2%
FY YoY: +90.6%
5Y CAGR: +12.7%
10Y CAGR: +5.7%

JNJ net income was $210.00M in fiscal Q3 2026 (ended Sep 27, 2026), down 95.9% from a year earlier and down 96.2% from the prior quarter. For the full fiscal 2025 it was $26.80B, up 90.6% from fiscal 2024. Compound annual growth was +12.7% over 5 years and +5.7% over 10 years. It rose in 5 of the last 10 fiscal years.

JNJ EPSQ3 2026$0.09

Quarter YoY: -95.8%
QoQ: -96.0%
FY YoY: +90.5%
5Y CAGR: +14.9%
10Y CAGR: +7.2%

JNJ diluted EPS was $0.09 in fiscal Q3 2026 (ended Sep 27, 2026), down 95.8% from a year earlier and down 96.0% from the prior quarter. For the full fiscal 2025 it was $11.03, up 90.5% from fiscal 2024. Compound annual growth was +14.9% over 5 years and +7.2% over 10 years.

JNJ free cash flowQ3 2026$6.36B

Quarter YoY: -20.6%
QoQ: -12.8%
FY YoY: -0.7%
5Y CAGR: -0.5%
10Y CAGR: +2.0%

JNJ free cash flow was $6.36B in fiscal Q3 2026 (ended Sep 27, 2026), down 20.6% from a year earlier and down 12.8% from the prior quarter. For the full fiscal 2025 it was $19.70B, down 0.7% from fiscal 2024. Compound annual growth was -0.5% over 5 years and +2.0% over 10 years. It rose in 6 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 28, 2025	FY2024 Dec 29, 2024	FY2023 Dec 31, 2023	FY2022 Jan 1, 2023	FY2021 Jan 2, 2022	FY2020 Jan 3, 2021	FY2019 Dec 29, 2019	FY2018 Dec 30, 2018	FY2017 Dec 31, 2017	FY2016 Jan 1, 2017
Revenue	$94.19B	$88.82B	$85.16B	$79.99B	$78.74B	$82.58B	$82.06B	$81.58B	$76.45B	$71.89B
Cost of revenue	$30.26B	$27.47B	$26.55B	$24.60B	$23.40B	$28.43B	$27.56B	$27.09B	$25.44B	$21.79B
Gross profit	$63.94B	$61.35B	$58.61B	$55.39B	$55.34B	$54.16B	$54.50B	$54.49B	$51.01B	$50.10B
Research and development	$109.00M	$1.84B	$483.00M	$0	$0	$12.16B	$11.36B	$10.78B	$10.59B	$9.14B
Selling, general and admin	$23.68B	$22.87B	$21.51B	$20.25B	$20.12B	$22.08B	$22.18B	$22.54B	$21.52B	$20.07B
Interest expense	$971.00M	$755.00M	$772.00M	$276.00M	$183.00M	$201.00M	$318.00M	$1.00B	$934.00M	$726.00M
Pre-tax income	$32.58B	$16.69B	$15.06B	$19.36B	$19.18B	$16.50B	$17.33B	$18.00B	$17.67B	$19.80B
Income tax	$5.78B	$2.62B	$1.74B	$2.99B	$1.38B	$1.78B	$2.21B	$2.70B	$16.37B	$3.26B
Net income	$26.80B	$14.07B	$35.15B	$17.94B	$20.88B	$14.71B	$15.12B	$15.30B	$1.30B	$16.54B
EPS, basic	$11.13	$5.84	$13.88	$6.83	$7.93	$5.59	$5.72	$5.70	$0.48	$6.04
EPS, diluted	$11.03	$5.79	$13.72	$6.73	$7.81	$5.51	$5.63	$5.61	$0.47	$5.93
Diluted shares	2.43B	2.43B	2.56B	2.66B	2.67B	2.67B	2.68B	2.73B	2.75B	2.79B

Balance sheet

Balance sheet
Line item	FY2025 Dec 28, 2025	FY2024 Dec 29, 2024	FY2023 Dec 31, 2023	FY2022 Jan 1, 2023	FY2021 Jan 2, 2022	FY2020 Jan 3, 2021	FY2019 Dec 29, 2019	FY2018 Dec 30, 2018	FY2017 Dec 31, 2017	FY2016 Jan 1, 2017
Cash and equivalents	$19.71B	$24.11B	$21.86B	$14.13B	$14.49B	$13.98B	$17.30B	$18.11B	$17.82B	$18.97B
Short-term investments	$393.00M	$417.00M	$1.07B	$9.39B	$17.12B	$11.20B	$1.98B	$1.58B	$472.00M	$22.93B
Receivables	$17.18B	$14.84B	$14.87B	$14.04B	$15.28B	$13.58B	$14.48B	$14.10B	$13.49B	$11.70B
Inventory	$14.19B	$12.44B	$11.18B	$10.27B	$10.39B	$9.34B	$9.02B	$8.60B	$8.77B	$8.14B
Current assets	$55.62B	$55.89B	$53.49B	$55.29B	$60.98B	$51.24B	$45.27B	$46.03B	$43.09B	$65.03B
Goodwill	$48.77B	$44.20B	$36.56B	$36.05B	$25.44B	$36.39B	$33.64B	$30.45B	$31.91B	$22.80B
Total assets	$199.21B	$180.10B	$167.56B	$187.38B	$182.02B	$174.89B	$157.73B	$152.95B	$157.30B	$141.21B
Current liabilities	$54.13B	$50.32B	$46.28B	$55.80B	$45.23B	$42.49B	$35.96B	$31.23B	$30.54B	$26.29B
Short-term debt	$8.49B	$6.00B	$3.50B	$12.80B	$3.80B	$2.60B	$1.20B	$2.80B	$3.90B	$4.70B
Long-term debt	$39.44B	$30.65B	$25.88B	$26.89B	$29.98B	$32.63B	$26.49B	$27.68B	$30.68B	$22.44B
Total debt	$47.93B	$36.65B	$29.38B	$39.69B	$33.78B	$35.23B	$27.69B	$30.48B	$34.58B	$27.14B
Total liabilities	$117.67B	$108.61B	$98.78B	$110.57B	$108.00B	$111.62B	$98.26B	$93.20B	$97.14B	$70.79B
Shareholders' equity	$81.54B	$71.49B	$68.77B	$76.80B	$74.02B	$63.28B	$59.47B	$59.75B	$60.16B	$70.42B

Cash flow

Cash flow
Line item	FY2025 Dec 28, 2025	FY2024 Dec 29, 2024	FY2023 Dec 31, 2023	FY2022 Jan 1, 2023	FY2021 Jan 2, 2022	FY2020 Jan 3, 2021	FY2019 Dec 29, 2019	FY2018 Dec 30, 2018	FY2017 Dec 31, 2017	FY2016 Jan 1, 2017
Operating cash flow	$24.53B	$24.27B	$22.79B	$21.19B	$23.41B	$23.54B	$23.42B	$22.20B	$21.06B	$18.77B
Capital expenditures	$4.83B	$4.42B	$4.54B	$4.01B	$3.65B	$3.35B	$3.50B	$3.67B	$3.28B	$3.23B
Free cash flow	$19.70B	$19.84B	$18.25B	$17.18B	$19.76B	$20.19B	$19.92B	$18.53B	$17.78B	$15.54B
Investing cash flow	-$23.59B	-$18.60B	$878.00M	-$12.37B	-$8.68B	-$20.82B	-$6.19B	-$3.17B	-$14.87B	-$4.76B
Financing cash flow	-$5.54B	-$3.13B	-$15.82B	-$8.87B	-$14.05B	-$6.12B	-$18.02B	-$18.51B	-$7.67B	-$8.55B
Share repurchases	$5.95B	$2.43B	$5.05B	$6.04B	$3.46B	$3.22B	$6.75B	$5.87B	$6.36B	$8.98B
Stock-based compensation	$1.35B	$1.18B	$1.16B	$1.14B	$1.14B	$1.00B	$977.00M	$978.00M	$962.00M	$878.00M
Depreciation and amortization	$7.50B	$7.34B	$7.49B	$6.97B	$7.39B	$7.23B	$7.01B	$6.93B	$5.64B	$3.75B

Key ratios

Key ratios
Line item	FY2025 Dec 28, 2025	FY2024 Dec 29, 2024	FY2023 Dec 31, 2023	FY2022 Jan 1, 2023	FY2021 Jan 2, 2022	FY2020 Jan 3, 2021	FY2019 Dec 29, 2019	FY2018 Dec 30, 2018	FY2017 Dec 31, 2017	FY2016 Jan 1, 2017
Revenue growth, YoY	6.0%	4.3%	6.5%	1.6%	-4.7%	0.6%	0.6%	6.7%	6.3%	-
Net income growth, YoY	90.6%	-60.0%	95.9%	-14.1%	41.9%	-2.7%	-1.2%	1076.7%	-92.1%	7.3%
EPS growth, YoY	90.5%	-57.8%	103.9%	-13.8%	41.7%	-2.1%	0.4%	1093.6%	-92.1%	8.2%
Gross margin	67.9%	69.1%	68.8%	69.3%	70.3%	65.6%	66.4%	66.8%	66.7%	69.7%
Net margin	28.5%	15.8%	41.3%	22.4%	26.5%	17.8%	18.4%	18.8%	1.7%	23.0%
Free cash flow margin	20.9%	22.3%	21.4%	21.5%	25.1%	24.4%	24.3%	22.7%	23.3%	21.6%
Return on equity	32.9%	19.7%	51.1%	23.4%	28.2%	23.3%	25.4%	25.6%	2.2%	23.5%
Return on assets	13.5%	7.8%	21.0%	9.6%	11.5%	8.4%	9.6%	10.0%	0.8%	11.7%
Current ratio	1.03	1.11	1.16	0.99	1.35	1.21	1.26	1.47	1.41	2.47
Debt to equity	0.59	0.51	0.43	0.52	0.46	0.56	0.47	0.51	0.57	0.39

Income statement

Income statement
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 28, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 29, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Revenue	$25.40B	$25.31B	$24.06B	$24.56B	$23.99B	$23.74B	$21.89B	$22.52B	$22.47B	$22.45B	$21.38B	$21.39B
Cost of revenue	$8.10B	$8.05B	$8.11B	$7.97B	$7.30B	$7.63B	$7.36B	$7.13B	$6.96B	$6.87B	$6.51B	$6.80B
Gross profit	$17.30B	$17.26B	$15.96B	$16.60B	$16.69B	$16.11B	$14.54B	$15.39B	$15.51B	$15.58B	$14.87B	$14.60B
Research and development	$4.65B	$3.65B	$3.53B	-$10.30B	$3.67B	$3.52B	$3.23B	-$10.09B	$4.95B	$3.44B	$3.54B	-$10.12B
Selling, general and admin	$6.29B	$6.43B	$6.03B	$6.75B	$5.92B	$5.89B	$5.11B	$6.45B	$5.48B	$5.68B	$5.26B	$5.81B
Interest expense	$217.00M	$281.00M	$272.00M	$214.00M	$245.00M	$308.00M	$204.00M	$137.00M	$193.00M	$270.00M	$155.00M	$151.00M
Pre-tax income	$34.00M	$6.75B	$5.99B	$4.97B	$7.49B	$6.49B	$13.63B	$3.89B	$3.34B	$5.75B	$3.71B	$4.83B
Income tax	-$176.00M	$1.21B	$755.00M	-$150.00M	$2.34B	$954.00M	$2.63B	$456.00M	$644.00M	$1.06B	$459.00M	$694.00M
Net income	$210.00M	$5.53B	$5.24B	$5.12B	$5.15B	$5.54B	$11.00B	$3.43B	$2.69B	$4.69B	$3.25B	$4.05B
EPS, basic	$0.09	$2.30	$2.17	$2.12	$2.14	$2.30	$4.57	$1.42	$1.12	$1.95	$1.35	$1.68
EPS, diluted	$0.09	$2.27	$2.14	$2.08	$2.12	$2.29	$4.54	$1.41	$1.11	$1.93	$1.34	$1.67
Diluted shares	2.45B	2.44B	2.45B	-	2.43B	2.42B	2.42B	-	2.43B	2.42B	2.43B	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 28, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 29, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Cash and equivalents	$16.91B	$20.42B	$21.69B	$19.71B	$18.23B	$18.58B	$38.47B	$24.11B	$19.98B	$24.88B	$25.47B	$21.86B
Short-term investments	$318.00M	$336.00M	$363.00M	$393.00M	$331.00M	$303.00M	$307.00M	$417.00M	$317.00M	$597.00M	$745.00M	$1.07B
Receivables	$18.99B	$19.05B	$17.72B	$17.18B	$17.61B	$17.85B	$16.02B	$14.84B	$16.17B	$15.79B	$14.95B	$14.87B
Inventory	$15.38B	$15.14B	$14.58B	$14.19B	$14.15B	$13.41B	$12.66B	$12.44B	$12.60B	$12.17B	$11.38B	$11.18B
Current assets	$56.35B	$59.77B	$59.17B	$55.62B	$54.61B	$54.50B	$71.55B	$55.89B	$53.25B	$57.82B	$57.00B	$53.49B
Goodwill	$48.47B	$48.48B	$48.56B	$48.77B	$48.05B	$48.12B	$44.47B	$44.20B	$44.80B	$44.25B	$36.62B	$36.56B
Total assets	$197.43B	$201.06B	$200.89B	$199.21B	$192.82B	$193.39B	$193.67B	$180.10B	$178.29B	$181.09B	$171.97B	$167.56B
Current liabilities	$55.46B	$54.90B	$57.72B	$54.13B	$50.87B	$54.18B	$56.90B	$50.32B	$51.76B	$53.93B	$48.73B	$46.28B
Short-term debt	$8.85B	$11.69B	$17.46B	$8.49B	$6.39B	$11.53B	$13.90B	$6.00B	$4.46B	$9.86B	$8.55B	$3.50B
Long-term debt	$35.80B	$37.34B	$37.53B	$39.44B	$39.41B	$39.23B	$38.35B	$30.65B	$31.29B	$31.64B	$25.08B	$25.88B
Total debt	$44.65B	$49.04B	$54.99B	$47.93B	$45.80B	$50.76B	$52.25B	$36.65B	$35.75B	$41.49B	$33.63B	$29.38B
Total liabilities	$115.90B	$116.09B	$119.71B	$117.67B	$113.54B	$114.92B	$115.56B	$108.61B	$108.13B	$109.55B	$101.95B	$98.78B
Shareholders' equity	$81.53B	$84.97B	$81.19B	$81.54B	$79.28B	$78.47B	$78.11B	$71.49B	$70.16B	$71.54B	$70.02B	$68.77B

Cash flow

Cash flow
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 28, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 29, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Operating cash flow	$7.72B	$8.62B	$2.51B	$7.31B	$9.17B	$3.88B	$4.17B	$6.98B	$7.99B	$5.63B	$3.66B	$7.86B
Capital expenditures	$1.36B	$1.32B	$1.05B	$1.84B	$1.16B	$1.04B	$795.00M	$1.61B	$1.03B	$976.00M	$807.00M	$1.59B
Free cash flow	$6.36B	$7.29B	$1.47B	$5.47B	$8.01B	$2.83B	$3.38B	$5.37B	$6.96B	$4.66B	$2.85B	$6.27B
Investing cash flow	-$2.71B	-$1.11B	-$1.04B	-$4.49B	-$542.00M	-$18.26B	-$297.00M	-$1.32B	-$3.13B	-$13.69B	-$464.00M	-$1.20B
Financing cash flow	-$8.53B	-$8.78B	$530.00M	-$1.37B	-$8.93B	-$5.67B	$10.42B	-$1.34B	-$9.88B	$7.54B	$546.00M	-$4.66B
Share repurchases	$1.71B	$221.00M	$4.03B	$1.92B	$1.90B	$0	$2.13B	$282.00M	$539.00M	$136.00M	$1.48B	$216.00M
Stock-based compensation	$357.00M	$458.00M	$300.00M	$309.00M	$347.00M	$410.00M	$288.00M	$238.00M	$295.00M	$341.00M	$302.00M	$178.00M
Depreciation and amortization	$2.12B	$1.96B	$2.00B	$2.01B	$1.78B	$1.94B	$1.77B	$1.90B	$1.85B	$1.78B	$1.81B	$1.84B

Key ratios

Key ratios
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 28, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 29, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Revenue growth, YoY	5.9%	6.6%	9.9%	9.1%	6.8%	5.8%	2.4%	5.3%	5.2%	4.3%	2.3%	7.3%
Net income growth, YoY	-95.9%	-0.1%	-52.4%	49.1%	91.2%	18.2%	237.9%	-15.3%	-89.6%	-8.9%	-	15.0%
EPS growth, YoY	-95.8%	-0.9%	-52.9%	47.5%	91.0%	18.7%	238.8%	-15.6%	-89.1%	-1.5%	-	25.6%
Gross margin	68.1%	68.2%	66.3%	67.6%	69.6%	67.9%	66.4%	68.3%	69.0%	69.4%	69.6%	68.2%
Net margin	0.8%	21.9%	21.8%	20.8%	21.5%	23.3%	50.2%	15.2%	12.0%	20.9%	15.2%	18.9%
Free cash flow margin	25.0%	28.8%	6.1%	22.3%	33.4%	11.9%	15.4%	23.8%	31.0%	20.7%	13.3%	29.3%
Current ratio	1.02	1.09	1.03	1.03	1.07	1.01	1.26	1.11	1.03	1.07	1.17	1.16
Debt to equity	0.55	0.58	0.68	0.59	0.58	0.65	0.67	0.51	0.51	0.58	0.48	0.43

Source: XBRL data Johnson & Johnson files with the SEC, latest filing dated Oct 21, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

JNJ peers

Company	Revenue	Growth	Net income	Net margin	Market cap
JNJ	$99.33B	+7.8%	$16.09B	16.2%	$664.95B
MRKMerck & Company Inc.	$67.38B	+4.9%	$2.45B	3.6%	$361.71B
NVSNovartis AG	$54.53B	+8.4%	$13.98B	25.6%	$310.17B
AZNAstraZeneca PLC	$58.74B	+8.6%	$10.22B	17.4%	$289.10B
PFEPfizer Inc.	$63.63B	+1.3%	$4.03B	6.3%	$167.49B
ULUnilever PLC	€50.50B	-3.8%	€9.47B	18.7%	$142.19B
GSKGSK plc	£32.67B	+4.1%	£5.72B	17.5%	$101.80B

JNJ FAQ

9 questions

What is JNJ revenue?
Johnson & Johnson (JNJ) reported $99.33B of revenue for the twelve months ended Sep 27, 2026. That is up 7.8% from the year before. Revenue for fiscal 2025 was $94.19B.
Is JNJ profitable?
Yes. Johnson & Johnson earned $16.09B in net income for the twelve months ended Sep 27, 2026, a net margin of 16.2%.
How much cash and debt does JNJ have?
Johnson & Johnson reported $16.91B in cash and cash equivalents and $44.65B of debt on its most recent balance sheet in SEC filings.
How fast is JNJ revenue growing?
Johnson & Johnson's revenue changed +6.0% in fiscal 2025, to $94.19B. Its compound annual growth rate was +2.7% over 5 years.
What is JNJ gross margin?
Johnson & Johnson's gross profit was $67.11B on $99.33B of revenue for the twelve months ended Sep 27, 2026, a gross margin of 67.6%.
What is JNJ free cash flow?
Johnson & Johnson generated $20.59B of free cash flow for the twelve months ended Sep 27, 2026, which is operating cash flow of $26.16B less capital expenditures.
What is JNJ earnings per share?
Diluted earnings per share were $6.58 for the twelve months ended Sep 27, 2026, from SEC filings, restated for any stock split those filings show.
When did JNJ last report financial results?
The latest statements here come from Johnson & Johnson's 10-Q filed on Oct 21, 2026, covering the period ended Sep 27, 2026.
Where does this JNJ financial data come from?
Quantisnow builds these statements from the structured XBRL data Johnson & Johnson files with the SEC. It is provided for information only and is not investment advice.